1. Market Research
  2. > Metastatic Cancer - Pipeline Review, H2 2013

Metastatic Cancer - Pipeline Review, H2 2013

  • September 2013
  • -
  • Global Markets Direct
  • -
  • 219 pages

Metastatic Cancer - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Metastatic Cancer - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metastatic Cancer. Metastatic Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Metastatic Cancer.
- A review of the Metastatic Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Metastatic Cancer pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Metastatic Cancer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Metastatic Cancer pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Metastatic Cancer - Pipeline Review, H2 2013
Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 8
Global Markets Direct Report Coverage 8
Metastatic Cancer Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Metastatic Cancer 10
Metastatic Cancer Therapeutics under Development by Companies 12
Metastatic Cancer Therapeutics under Investigation by Universities/Institutes 16
Late Stage Products 17
Comparative Analysis 17
Mid Clinical Stage Products 18
Comparative Analysis 18
Early Clinical Stage Products 19
Comparative Analysis 19
Discovery and Pre-Clinical Stage Products 20
Comparative Analysis 20
Metastatic Cancer Therapeutics - Products under Development by Companies 21
Metastatic Cancer Therapeutics - Products under Investigation by Universities/Institutes 25
Companies Involved in Metastatic Cancer Therapeutics Development 26
Bristol-Myers Squibb Company 26
Boehringer Ingelheim GmbH 27
F. Hoffmann-La Roche Ltd. 28
Amgen Inc. 29
Eli Lilly and Company 30
Merck and Co., Inc. 31
ZIOPHARM Oncology, Inc. 32
Aphios Corporation 33
SuperGen, Inc. 34
Celgene Corporation 35
AntiCancer, Inc. 36
Merck KGaA 37
EntreMed, Inc. 38
Circadian Technologies Limited 39
TapImmune Inc. 40
Hanall Pharmaceutical Co., Ltd. 41
Galapagos NV 42
Cancer Research Technology Limited 43
Glycotope GmbH 44
Altor BioScience Corporation 45
Provecs Medical GmbH 46
Alethia Biotherapeutics Inc. 47
Five Prime Therapeutics, Inc. 48
Merrimack Pharmaceuticals, Inc. 49
Deciphera Pharmaceuticals, LLC 50
MSM Protein Technologies, Inc. 51
Vascular Biogenics Ltd. 52
Advenchen Laboratories, LLC 53
Globeimmune, Inc. 54
BIND Biosciences, Inc. 55
TRACON Pharmaceuticals, Inc. 56
Medestea Research and Production S.p.A. 57
PharmAbcine, Inc. 58
ECI, Inc. 59
Faron Pharmaceuticals, Ltd. 60
Incuron 61
AngioLab, Inc. 62
Gradalis Inc. 63
Immunovative Therapies, Ltd. 64
Metastatic Cancer - Therapeutics Assessment 65
Assessment by Monotherapy Products 65
Assessment by Route of Administration 66
Assessment by Molecule Type 68
Drug Profiles 70
DI-17-E-6 - Drug Profile 70
ridaforolimus - Drug Profile 72
solitomab - Drug Profile 76
ENMD-2076 - Drug Profile 78
BMS-833923 - Drug Profile 80
Im-01 - Drug Profile 82
AT-9283 - Drug Profile 83
AT-7519 - Drug Profile 85
AT-13387 - Drug Profile 88
cetuximab biobetter - Drug Profile 91
APH-0912 - Drug Profile 92
FP-1039 - Drug Profile 93
CBL-0137 - Drug Profile 95
irinotecan sucrosofate - Drug Profile 96
palifosfamide tromethamine - Drug Profile 98
AB-16B5 - Drug Profile 100
AdhTAP - Drug Profile 101
YN-968D1 - Drug Profile 103
VB-111 - Drug Profile 106
panitumumab - Drug Profile 107
ALT-801 - Drug Profile 110
GLPG-0187 - Drug Profile 112
GI-6207 - Drug Profile 113
VGX-100 - Drug Profile 114
docetaxel targeted nanoparticles - Drug Profile 116
Aptamer-Targeted siRNA - Drug Profile 118
afatinib - Drug Profile 119
HL-156Can - Drug Profile 121
LY-2334737 - Drug Profile 122
LY-2780301 - Drug Profile 123
ARRY-382 - Drug Profile 124
MTLH-003 - Drug Profile 125
MTLH-004 - Drug Profile 126
EMD-521873 - Drug Profile 127
IT-235 - Drug Profile 128
ONCase-PEG - Drug Profile 129
TRC-102 - Drug Profile 130
MSB-0010360 - Drug Profile 132
trastuzumab biobetter - Drug Profile 133
GI-6301 - Drug Profile 135
Pbi-shRNA STMN1 LP - Drug Profile 136
MSM-057 - Drug Profile 137
MSM-165 - Drug Profile 138
MSM-112 - Drug Profile 139
DCC-2909 - Drug Profile 140
MetVac Vaccine - Drug Profile 141
TTAC-0001 - Drug Profile 142
LY-3039478 - Drug Profile 143
CytoPep - Drug Profile 144
Short Peptide Inhibitors Of MT1 MMP - Drug Profile 145
PRX-003 - Drug Profile 146
MSB-0010718C - Drug Profile 147
Phospholipase D Inhibitors - Drug Profile 148
Monoclonal Antibody Targeting Tyrosine Phosphatase DEP-1 - Drug Profile 149
ABC Transporter Inhibitors - Drug Profile 150
Anti-S100A4 Monoclonal Antibody - Drug Profile 151
KN-014 - Drug Profile 152
U-94 - Drug Profile 153
Integrin Alpha5Beta1 Inhibitor - Drug Profile 154
Q-4 - Drug Profile 155
Tumour Anti Invasive Compounds - Drug Profile 156
HSA-TIMP-2 - Drug Profile 157
AMX-3002 - Drug Profile 158
DP-6865 - Drug Profile 159
Laulimalide Derivatives - Drug Profile 160
Pegylated IL-10 - Drug Profile 161
Metastatic Cancer Therapeutics - Drug Profile Updates 162
Metastatic Cancer Therapeutics - Discontinued Products 206
Metastatic Cancer Therapeutics - Dormant Products 207
Metastatic Cancer - Product Development Milestones 209
Featured News and Press Releases 209
Appendix 214
Methodology 214
Coverage 214
Secondary Research 214
Primary Research 214
Expert Panel Validation 214
Contact Us 215
Disclaimer 215



List of Tables

Number of Products Under Development for Metastatic Cancer, H2 2013 15
Products under Development for Metastatic Cancer - Comparative Analysis, H2 2013 16
Number of Products under Development by Companies, H2 2013 18
Number of Products under Development by Companies, H2 2013 (Contd..1) 19
Number of Products under Development by Companies, H2 2013 (Contd..2) 20
Number of Products under Investigation by Universities/Institutes, H2 2013 21
Comparative Analysis by Late Stage Development, H2 2013 22
Comparative Analysis by Mid Clinical Stage Development, H2 2013 23
Comparative Analysis by Early Clinical Stage Development, H2 2013 24
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 25
Products under Development by Companies, H2 2013 26
Products under Development by Companies, H2 2013 (Contd..1) 27
Products under Development by Companies, H2 2013 (Contd..2) 28
Products under Development by Companies, H2 2013 (Contd..3) 29
Products under Investigation by Universities/Institutes, H2 2013 30
Bristol-Myers Squibb Company, H2 2013 31
Boehringer Ingelheim GmbH, H2 2013 32
F. Hoffmann-La Roche Ltd., H2 2013 33
Amgen Inc., H2 2013 34
Eli Lilly and Company, H2 2013 35
Merck and Co., Inc., H2 2013 36
ZIOPHARM Oncology, Inc., H2 2013 37
Aphios Corporation, H2 2013 38
SuperGen, Inc., H2 2013 39
Celgene Corporation, H2 2013 40
AntiCancer, Inc., H2 2013 41
Merck KGaA, H2 2013 42
EntreMed, Inc., H2 2013 43
Circadian Technologies Limited, H2 2013 44
TapImmune Inc., H2 2013 45
Hanall Pharmaceutical Co., Ltd., H2 2013 46
Galapagos NV, H2 2013 47
Cancer Research Technology Limited, H2 2013 48
Glycotope GmbH, H2 2013 49
Altor BioScience Corporation, H2 2013 50
Provecs Medical GmbH, H2 2013 51
Alethia Biotherapeutics Inc., H2 2013 52
Five Prime Therapeutics, Inc., H2 2013 53
Merrimack Pharmaceuticals, Inc., H2 2013 54
Deciphera Pharmaceuticals, LLC, H2 2013 55
MSM Protein Technologies, Inc., H2 2013 56
Vascular Biogenics Ltd., H2 2013 57
Advenchen Laboratories, LLC, H2 2013 58
Globeimmune, Inc., H2 2013 59
BIND Biosciences, Inc., H2 2013 60
TRACON Pharmaceuticals, Inc., H2 2013 61
Medestea Research and Production S.p.A., H2 2013 62
PharmAbcine, Inc., H2 2013 63
ECI, Inc., H2 2013 64
Faron Pharmaceuticals, Ltd., H2 2013 65
Incuron, H2 2013 66
AngioLab, Inc., H2 2013 67
Gradalis Inc., H2 2013 68
Immunovative Therapies, Ltd., H2 2013 69
Assessment by Monotherapy Products, H2 2013 70
Assessment by Stage and Route of Administration, H2 2013 72
Assessment by Stage and Molecule Type, H2 2013 74
Metastatic Cancer Therapeutics - Drug Profile Updates 167
Metastatic Cancer Therapeutics - Discontinued Products 211
Metastatic Cancer Therapeutics - Dormant Products 212
Metastatic Cancer Therapeutics - Dormant Products (Contd..2) 213



List of Figures

Number of Products under Development for Metastatic Cancer, H2 2013 15
Products under Development for Metastatic Cancer - Comparative Analysis, H2 2013 16
Products under Development by Companies, H2 2013 17
Products under Investigation by Universities/Institutes, H2 2013 21
Late Stage Products, H2 2013 22
Mid Clinical Stage Products, H2 2013 23
Early Clinical Stage Products, H2 2013 24
Discovery and Pre-Clinical Stage Products, H2 2013 25
Assessment by Monotherapy Products, H2 2013 70
Assessment by Route of Administration, H2 2013 71
Assessment by Stage and Route of Administration, H2 2013 72
Assessment by Molecule Type, H2 2013 73
Assessment by Stage and Molecule Type, H2 2013 74



Companies Mentioned

Bristol-Myers Squibb Company
Boehringer Ingelheim GmbH
F. Hoffmann-La Roche Ltd.
Amgen Inc.
Eli Lilly and Company
Merck and Co., Inc.
ZIOPHARM Oncology, Inc.
Aphios Corporation
SuperGen, Inc.
Celgene Corporation
AntiCancer, Inc.
Merck KGaA
EntreMed, Inc.
Circadian Technologies Limited
TapImmune Inc.
Hanall Pharmaceutical Co., Ltd.
Galapagos NV
Cancer Research Technology Limited
Glycotope GmbH
Altor BioScience Corporation
Provecs Medical GmbH
Alethia Biotherapeutics Inc.
Five Prime Therapeutics, Inc.
Merrimack Pharmaceuticals, Inc.
Deciphera Pharmaceuticals, LLC
MSM Protein Technologies, Inc.
Vascular Biogenics Ltd.
Advenchen Laboratories, LLC
Globeimmune, Inc.
BIND Biosciences, Inc.
TRACON Pharmaceuticals, Inc.
Medestea Research and Production S.p.A.
PharmAbcine, Inc.
ECI, Inc.
Faron Pharmaceuticals, Ltd.
Incuron
AngioLab, Inc.
Gradalis Inc.
Immunovative Therapies, Ltd.

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.